Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer: Comparison with triple therapy

C. Ganesh Pai, C. P. Thomas, Asok Biswas, Sugandhi Rao, K. Ramnarayan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Quadruple therapy appears to be more effective than standard triple therapy in the management of patients with Helicobacter pylori infection who harbor drug-resistant organisms. No data are available on the relative efficacies of triple and quadruple drug regimens from India. Methods: Consecutive patients with peptic ulcer and H. pylori infection were randomized to receive lansoprazole 30 mg twice daily along with either amoxycillin (500 mg four times daily) and clarithromycin (500 mg twice a day) (Group A), or tri-potassium dicitrato bismuthate (120 mg four times daily), metronidazole (400 mg thrice daily) and tetracycline (500 mg 4 times daily) (Group B) for 10 days. Presence of H. pylori infection was looked for using an in-house urease test and histology before starting treatment, and 30 days after completion of treatment. Results: Twenty-nine of 35 patients in Group A and 24 of 33 in Group B had eradication of infection (82.8% and 72.7% by intention-to-treat analysis, and 87.9% and 85.7% by per protocol analysis, respectively; p=ns). Side-effects occurred in 4 (12%) and 5 (18%) patients in Groups A and B, respectively (p=ns); discontinuation of drugs was required in two patients in group B. Conclusions: Quadruple therapy for initial treatment of H. pylori infection does not offer any advantage over standard triple therapy in Indian patients.

Original languageEnglish
Pages (from-to)85-87
Number of pages3
JournalIndian Journal of Gastroenterology
Volume22
Issue number3
Publication statusPublished - 01-05-2003

Fingerprint

Peptic Ulcer
Helicobacter pylori
Helicobacter Infections
Therapeutics
Pharmaceutical Preparations
Lansoprazole
Intention to Treat Analysis
Clarithromycin
Urease
Amoxicillin
Metronidazole
Tetracycline
India
Histology
Potassium
Infection

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Pai, C. Ganesh ; Thomas, C. P. ; Biswas, Asok ; Rao, Sugandhi ; Ramnarayan, K. / Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer : Comparison with triple therapy. In: Indian Journal of Gastroenterology. 2003 ; Vol. 22, No. 3. pp. 85-87.
@article{9ee5e36b92e24085bc4578745db9e1d7,
title = "Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer: Comparison with triple therapy",
abstract = "Background: Quadruple therapy appears to be more effective than standard triple therapy in the management of patients with Helicobacter pylori infection who harbor drug-resistant organisms. No data are available on the relative efficacies of triple and quadruple drug regimens from India. Methods: Consecutive patients with peptic ulcer and H. pylori infection were randomized to receive lansoprazole 30 mg twice daily along with either amoxycillin (500 mg four times daily) and clarithromycin (500 mg twice a day) (Group A), or tri-potassium dicitrato bismuthate (120 mg four times daily), metronidazole (400 mg thrice daily) and tetracycline (500 mg 4 times daily) (Group B) for 10 days. Presence of H. pylori infection was looked for using an in-house urease test and histology before starting treatment, and 30 days after completion of treatment. Results: Twenty-nine of 35 patients in Group A and 24 of 33 in Group B had eradication of infection (82.8{\%} and 72.7{\%} by intention-to-treat analysis, and 87.9{\%} and 85.7{\%} by per protocol analysis, respectively; p=ns). Side-effects occurred in 4 (12{\%}) and 5 (18{\%}) patients in Groups A and B, respectively (p=ns); discontinuation of drugs was required in two patients in group B. Conclusions: Quadruple therapy for initial treatment of H. pylori infection does not offer any advantage over standard triple therapy in Indian patients.",
author = "Pai, {C. Ganesh} and Thomas, {C. P.} and Asok Biswas and Sugandhi Rao and K. Ramnarayan",
year = "2003",
month = "5",
day = "1",
language = "English",
volume = "22",
pages = "85--87",
journal = "Indian Journal of Gastroenterology",
issn = "0254-8860",
publisher = "Indian Society of Gastroenterology",
number = "3",

}

Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer : Comparison with triple therapy. / Pai, C. Ganesh; Thomas, C. P.; Biswas, Asok; Rao, Sugandhi; Ramnarayan, K.

In: Indian Journal of Gastroenterology, Vol. 22, No. 3, 01.05.2003, p. 85-87.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer

T2 - Comparison with triple therapy

AU - Pai, C. Ganesh

AU - Thomas, C. P.

AU - Biswas, Asok

AU - Rao, Sugandhi

AU - Ramnarayan, K.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Background: Quadruple therapy appears to be more effective than standard triple therapy in the management of patients with Helicobacter pylori infection who harbor drug-resistant organisms. No data are available on the relative efficacies of triple and quadruple drug regimens from India. Methods: Consecutive patients with peptic ulcer and H. pylori infection were randomized to receive lansoprazole 30 mg twice daily along with either amoxycillin (500 mg four times daily) and clarithromycin (500 mg twice a day) (Group A), or tri-potassium dicitrato bismuthate (120 mg four times daily), metronidazole (400 mg thrice daily) and tetracycline (500 mg 4 times daily) (Group B) for 10 days. Presence of H. pylori infection was looked for using an in-house urease test and histology before starting treatment, and 30 days after completion of treatment. Results: Twenty-nine of 35 patients in Group A and 24 of 33 in Group B had eradication of infection (82.8% and 72.7% by intention-to-treat analysis, and 87.9% and 85.7% by per protocol analysis, respectively; p=ns). Side-effects occurred in 4 (12%) and 5 (18%) patients in Groups A and B, respectively (p=ns); discontinuation of drugs was required in two patients in group B. Conclusions: Quadruple therapy for initial treatment of H. pylori infection does not offer any advantage over standard triple therapy in Indian patients.

AB - Background: Quadruple therapy appears to be more effective than standard triple therapy in the management of patients with Helicobacter pylori infection who harbor drug-resistant organisms. No data are available on the relative efficacies of triple and quadruple drug regimens from India. Methods: Consecutive patients with peptic ulcer and H. pylori infection were randomized to receive lansoprazole 30 mg twice daily along with either amoxycillin (500 mg four times daily) and clarithromycin (500 mg twice a day) (Group A), or tri-potassium dicitrato bismuthate (120 mg four times daily), metronidazole (400 mg thrice daily) and tetracycline (500 mg 4 times daily) (Group B) for 10 days. Presence of H. pylori infection was looked for using an in-house urease test and histology before starting treatment, and 30 days after completion of treatment. Results: Twenty-nine of 35 patients in Group A and 24 of 33 in Group B had eradication of infection (82.8% and 72.7% by intention-to-treat analysis, and 87.9% and 85.7% by per protocol analysis, respectively; p=ns). Side-effects occurred in 4 (12%) and 5 (18%) patients in Groups A and B, respectively (p=ns); discontinuation of drugs was required in two patients in group B. Conclusions: Quadruple therapy for initial treatment of H. pylori infection does not offer any advantage over standard triple therapy in Indian patients.

UR - http://www.scopus.com/inward/record.url?scp=0038122868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038122868&partnerID=8YFLogxK

M3 - Article

C2 - 12839378

AN - SCOPUS:0038122868

VL - 22

SP - 85

EP - 87

JO - Indian Journal of Gastroenterology

JF - Indian Journal of Gastroenterology

SN - 0254-8860

IS - 3

ER -